

Kenneth Kin Wah To

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8500137/kenneth-kin-wah-to-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

5,078
citations

38
h-index

68
g-index

143
ext. papers

5,852
ext. citations

6.7
avg, IF

5.83
L-index

#	Paper	IF	Citations
122	Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells i, , and .. <i>Molecular Therapy - Oncolytics</i> , 2022 , 24, 636-649	6.4	0
121	Association of serum 25(OH)Vit-D levels with risk of pediatric fractures: a systematic review and meta-analysis. <i>Osteoporosis International</i> , 2021 , 32, 1287-1300	5.3	5
120	Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. <i>Advanced Science</i> , 2021 , 8, 2003404	13.6	7
119	Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and J. Ellis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 622040	5.6	0
118	Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2021 , 16, 204-221	2.6	0
117	Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms. <i>Current Cancer Drug Targets</i> , 2021 , 21, 289-305	2.8	3
116	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. <i>Frontiers in Oncology</i> , 2021 , 11, 635007	5.3	19
115	Development of thermosensitive hydrogel wound dressing containing Acinetobacter baumannii phage against wound infections. <i>International Journal of Pharmaceutics</i> , 2021 , 602, 120508	6.5	7
114	An overview of rational design of mRNA-based therapeutics and vaccines. <i>Expert Opinion on Drug Discovery</i> , 2021 , 16, 1307-1317	6.2	6
113	Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy and. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 1885-1902	15.5	1
112	The prospects of tumor chemosensitivity testing at the single-cell level. <i>Drug Resistance Updates</i> , 2021 , 54, 100741	23.2	1
111	Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin. <i>British Journal of Pharmacology</i> , 2021 , 178, 582-599	8.6	1
110	The Influence of Formulation Components and Environmental Humidity on Spray-Dried Phage Powders for Treatment of Respiratory Infections Caused by. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
109	Formulation strategies for bacteriophages to target intracellular bacterial pathogens. <i>Advanced Drug Delivery Reviews</i> , 2021 , 176, 113864	18.5	8
108	Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. <i>Molecular Cancer</i> , 2021 , 20, 17	42.1	16
107	Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells. <i>Cancer Treatment and Research Communications</i> , 2020 , 25, 100229	2	1
106	Reversal of ABCB1-related multidrug resistance by ERK5-IN-1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 50	12.8	7

105	Drug transporters in the development of multidrug resistance in colorectal cancer 2020 , 35-55		3
104	CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. <i>Molecular Therapy - Oncolytics</i> , 2020 , 16, 100-110	6.4	6
103	Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells and o. <i>Acta Pharmaceutica Sinica B</i> , 2020 , 10, 799-811	15.5	9
102	Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments. <i>Expert Opinion on Drug Discovery</i> , 2020 , 15, 63-83	6.2	25
101	Updates on the use of liposomes for active tumor targeting in cancer therapy. <i>Nanomedicine</i> , 2020 , 15, 303-318	5.6	47
100	In vivo biocompatibility and efficacy of dexamethasone-loaded PLGA-PEG-PLGA thermogel in an alkali-burn induced corneal neovascularization disease model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020 , 155, 190-198	5.7	8
99	Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer. <i>Life Sciences</i> , 2020 , 262, 118522	6.8	3
98	Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases. <i>Life Sciences</i> , 2020 , 258, 118211	6.8	9
97	Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 141	21	13
96	Drug repurposing to overcome resistance to various therapies for colorectal cancer. <i>Cellular and Molecular Life Sciences</i> , 2019 , 76, 3383-3406	10.3	26
95	Biodegradable Thermosensitive PLGA-PEG-PLGA Polymer for Non-irritating and Sustained Ophthalmic Drug Delivery. <i>AAPS Journal</i> , 2019 , 21, 59	3.7	24
94	Oral delivery of paclitaxel by polymeric micelles: A comparison of different block length on uptake, permeability and oral bioavailability. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019 , 184, 110554	6	19
93	The RNA Binding Protein HuR: A Promising Drug Target for Anticancer Therapy. <i>Current Cancer Drug Targets</i> , 2019 , 19, 382-399	2.8	24
92	PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. <i>European Journal of Pharmacology</i> , 2018 , 823, 19-26	5.3	20
91	Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 31	12.8	17
90	CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance. <i>Investigational New Drugs</i> , 2018 , 36, 10-19	4.3	13
89	Recent Advances in the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 227	5.3	165
88	PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2018 , 48, 2302-2317	3.9	5

87	MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. <i>World Journal of Gastroenterology</i> , 2018 , 24, 2949-2973	5.6	93
86	Olmudinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 and. <i>Acta Pharmaceutica Sinica B</i> , 2018 , 8, 563-574	15.5	18
85	A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development. <i>Molecular Carcinogenesis</i> , 2017 , 56, 464-477	5	16
84	New Pt-NNSO core anticancer agents: Structural optimization and investigation of their anticancer activity. <i>Journal of Inorganic Biochemistry</i> , 2017 , 170, 34-45	4.2	2
83	Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. <i>Lung Cancer</i> , 2017 , 103, 58-65	5.9	27
82	Reversal of multidrug resistance by <i>Marsdenia tenacissima</i> and its main active ingredients polyoxypregnanes. <i>Journal of Ethnopharmacology</i> , 2017 , 203, 110-119	5	30
81	Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. <i>Experimental and Molecular Medicine</i> , 2017 , 49, e303	12.8	25
80	Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. <i>Cancer Letters</i> , 2017 , 405, 100-110	9.9	59
79	Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2017 , 124, 29-42	6	28
78	Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer. <i>Frontiers in Oncology</i> , 2017 , 7, 288	5.3	6
77	Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer. <i>Data in Brief</i> , 2016 , 7, 437-44	1.2	6
76	Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016 , 140, 278-286	6	36
75	Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016 , 139, 249-58	6	23
74	Monofunctional Platinum (PtII) Compounds - Shifting the Paradigm in Designing New Pt-based Anticancer Agents. <i>Current Medicinal Chemistry</i> , 2016 , 23, 1268-85	4.3	8
73	A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors. <i>Scientific Reports</i> , 2016 , 6, 25363	4.9	6
72	Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1845-58	6.1	34
71	Polyoxypregnane steroids with an open-chain sugar moiety from <i>Marsdenia tenacissima</i> and their chemoresistance reversal activity. <i>Phytochemistry</i> , 2016 , 126, 47-58	4	14
70	Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1471-1478	2.8	11

69	Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. <i>Biochemical Pharmacology</i> , 2015 , 97, 27-37	6	27
68	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015 , 101, 560-72	6.8	39
67	Sensitivity of apoptosis-resistant colon cancer cells to tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity. <i>Phytomedicine</i> , 2015 , 22, 536-44	6.5	63
66	Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. <i>Experimental Cell Research</i> , 2015 , 338, 222-31	4.2	67
65	Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells. <i>Journal of Pharmacological Sciences</i> , 2015 , 129, 210-5	3.7	10
64	Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer. <i>British Journal of Pharmacology</i> , 2015 , 172, 4089-106	8.6	20
63	Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. <i>Oncotarget</i> , 2015 , 6, 44643-59	3.3	26
62	A gold@polydopamine core-shell nanoprobe for long-term intracellular detection of microRNAs in differentiating stem cells. <i>Journal of the American Chemical Society</i> , 2015 , 137, 7337-46	16.4	164
61	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. <i>Oncotarget</i> , 2015 , 6, 17738-52	3.3	13
60	Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells. <i>Oncotarget</i> , 2015 , 6, 40850-65	3.3	9
59	Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: a 6-month randomized, double-blind, and placebo-controlled trial in equol-producing postmenopausal women. <i>Molecular Nutrition and Food Research</i> , 2014 , 58, 709-17	5.9	51
58	Polyoxypregnane steroids from the stems of <i>Marsdenia tenacissima</i> . <i>Journal of Natural Products</i> , 2014 , 77, 2044-53	4.9	23
57	Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of <i>Salvia miltiorrhiza</i> . <i>Phytomedicine</i> , 2014 , 21, 1264-72	6.5	70
56	Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells. <i>Cancer Research</i> , 2014 , 74, 4431-45	10.1	42
55	CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. <i>Biochemical Pharmacology</i> , 2014 , 91, 144-56	6	15
54	Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments. <i>Pharmacogenomics</i> , 2014 , 15, 1091-104	2.6	15
53	Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. <i>Oncotarget</i> , 2014 , 5, 11971-85	3.3	52
52	UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter. <i>American Journal of Cancer Research</i> , 2014 , 4, 148-60	4.4	5

51	Antitumor effects of novel compound, guttiferone K, on colon cancer by p21Waf1/Cip1-mediated G(0)/G(1) cell cycle arrest and apoptosis. <i>International Journal of Cancer</i> , 2013 , 132, 707-16	7.5	42
50	MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. <i>Journal of Biomedical Science</i> , 2013 , 20, 99	13.3	53
49	Reversal of ABCG2-mediated multidrug resistance by human cathelicidin and its analogs in cancer cells. <i>Peptides</i> , 2013 , 40, 13-21	3.8	9
48	Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation. <i>Cancer Letters</i> , 2013 , 328, 83-94	9.9	29
47	Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPAR α agonists. <i>British Journal of Pharmacology</i> , 2013 , 170, 1137-51	8.6	27
46	Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. <i>Cancer Biology and Therapy</i> , 2013 , 14, 175-83	4.6	13
45	Volasertib (BI 6727), a novel polo-like kinase inhibitor, reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cells. <i>Journal of Cancer Therapeutics & Research</i> , 2013 , 2, 13		4
44	An efficient way of studying protein-protein interactions involving HIF-1 α -Myc, and Sp1. <i>Methods in Molecular Biology</i> , 2013 , 1012, 77-84	1.4	2
43	Reversal of P-glycoprotein mediated multidrug resistance by Cryptotanshinone and Dihydrocryptotanshinone. <i>FASEB Journal</i> , 2013 , 27, 1093.15	0.9	
42	Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic β -aminoxy peptidomimetic. <i>International Journal of Pharmaceutics</i> , 2012 , 424, 33-9	6.5	20
41	Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutic drugs in side population cells and ABCB1-overexpressing leukemia cells. <i>Biochemical Pharmacology</i> , 2012 , 83, 586-97	6	95
40	Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. <i>British Journal of Pharmacology</i> , 2012 , 166, 1669-83	8.6	72
39	Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. <i>Molecular Medicine</i> , 2012 , 18, 887-98	6.2	41
38	Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. <i>Molecular Carcinogenesis</i> , 2012 , 51, 449-64	5	40
37	Adverse Cell Culture Conditions Mimicking the Tumor Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More Malignant Phenotype. <i>ISRN Oncology</i> , 2012 , 2012, 746025		16
36	Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. <i>European Journal of Cancer</i> , 2011 , 47, 1990-9	7.5	19
35	The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 49-62	5.5	36
34	Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. <i>Leukemia Research</i> , 2011 , 35, 73-9	2.7	9

33	Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. <i>Molecular Cancer Research</i> , 2011 , 9, 516-27	6.6	38
32	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 148, 256-67	4.5	65
31	Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi. <i>Marine Drugs</i> , 2010 , 8, 1469-81	6	68
30	Anticancer effect and structure-activity analysis of marine products isolated from metabolites of mangrove fungi in the South China Sea. <i>Marine Drugs</i> , 2010 , 8, 1094-105	6	19
29	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. <i>Cancer Research</i> , 2010 , 70, 7981-91	10.1	255
28	Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. <i>Chinese Medicine</i> , 2010 , 5, 26	4.7	53
27	Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2959-68	6.1	97
26	ABCG2: a perspective. <i>Advanced Drug Delivery Reviews</i> , 2009 , 61, 3-13	18.5	349
25	Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. <i>PLoS ONE</i> , 2009 , 4, e5172	3.7	71
24	Multidrug Resistance Mediated by MDR-ABC Transporters 2009 , 1-20		3
23	Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. <i>British Journal of Cancer</i> , 2008 , 98, 1515-24	8.7	86
22	Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. <i>Molecular Cancer Research</i> , 2008 , 6, 151-64	6.6	108
21	Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. <i>Molecular Pharmacology</i> , 2008 , 73, 490-7	4.3	33
20	Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. <i>Molecular and Cellular Biology</i> , 2008 , 28, 5147-61	4.8	131
19	ABCG2: determining its relevance in clinical drug resistance. <i>Cancer and Metastasis Reviews</i> , 2007 , 26, 39-57	9.6	296
18	Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. <i>Cell Cycle</i> , 2007 , 6, 1919-26	4.7	50
17	Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. <i>Molecular and Cellular Biology</i> , 2006 , 26, 8572-85	4.8	103
16	Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. <i>Anti-Cancer Drugs</i> , 2006 , 17, 673-83	2.4	23

15	The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. <i>EMBO Journal</i> , 2006 , 25, 4784-94	13	95
14	Genetic instability: the dark side of the hypoxic response. <i>Cell Cycle</i> , 2005 , 4, 881-2	4.7	27
13	HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. <i>Molecular Cell</i> , 2005 , 17, 793-803	17.6	296
12	Synergistic interaction between platinum-based antitumor agents and demethylcantharidin. <i>Cancer Letters</i> , 2005 , 223, 227-37	9.9	9
11	In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents. <i>Anti-Cancer Drugs</i> , 2005 , 16, 825-35	2.4	15
10	Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. <i>Journal of Biological Chemistry</i> , 2005 , 280, 38102-7	5.4	74
9	Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. <i>FASEB Journal</i> , 2004 , 18, 1028-30	0.9	58
8	Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin. <i>Bioorganic and Medicinal Chemistry</i> , 2004 , 12, 4565-73	3.4	27
7	Genomic organization and functional characterization of the human concentrative nucleoside transporter-3 isoform (hCNT3) expressed in mammalian cells. <i>Pflugers Archiv European Journal of Physiology</i> , 2003 , 447, 195-204	4.6	27
6	Platinum-based anticancer agents: innovative design strategies and biological perspectives. <i>Medicinal Research Reviews</i> , 2003 , 23, 633-55	14.4	279
5	Determination of the release of hydrolyzed demethylcantharidin from novel traditional chinese medicine-platinum compounds with anticancer activity by gas chromatography. <i>Journal of Chromatography A</i> , 2002 , 947, 319-26	4.5	9
4	Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 2065-8	8.3	69
3	Comparison of the vascular relaxant effects of ATP-dependent K ⁺ channel openers on aorta and pulmonary artery isolated from spontaneously hypertensive and Wistar-Kyoto rats. <i>European Journal of Pharmacology</i> , 1999 , 365, 241-51	5.3	27
2	Development of an enzyme-linked immunosorbent assay with monoclonal antibody for quantification of homovanillic in human urine samples. <i>Clinical Chemistry</i> , 1998 , 44, 1674-1679	5.5	8
1	Breast Cancer Resistance Protein319-358		8